关于盟科
公司简介
管理团队
愿景与使命
发展历程
联系我们
科学研究
抗生素耐药性
肾病靶向治疗
盟科研发模式
发表文献
研发管线
新闻中心
新闻发布
投资者关系
公司治理
临时公告
定期报告
投资者服务
股票信息
加入我们
联系我们
En
科学研究
以良药求良效。
首页
发表文献
抗生素耐药性
肾病靶向治疗
盟科研发模式
发表文献
Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens
Antimicrobial Agents and Chemotherapy / 2020
View Publication
In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe
Antimicrob Agents Chemother / 2020
View Publication
Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers
Antimicrob Agents Chemother / 2020
View Publication
Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent,in Chinese Patients
Clinical Therapeutics / 2020
View Publication
Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis
Clinical Therapeutics / 2019
View Publication
Concentration–response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent
J Pharmacokinet Pharmacodyn / 2019
View Publication
Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.
Clinical Therapeutics / 2018
View Publication
In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis
Antimicrob Agents Chemother / 2018
View Publication
Single- and Multiple-Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I Versus Linezolid in Healthy Adult Subjects
Antimicrob Agents Chemother / 2017
View Publication
Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes
Drug Metab Dispos / 2015
View Publication
New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile
J Med Chem / 2014
View Publication
Selection and characterization of Staphylococcus aureus mutants with reduced susceptibility to the investigational oxazolidinone MRX-I
Int J Antimicrob Agents / 2014
View Publication
<
1
2
3
>
关闭